Provera


Also found in: Dictionary, Thesaurus, Wikipedia.

Provera

 [pro-ver´ah]
trademark for preparations of medroxyprogesterone acetate, a progestational agent.

medroxyprogesterone acetate

Apo-Medroxy (CA), Climanor (UK), Depo-Provera, Depo-SUBQ-Provera 104, Dom-Medroxyprogesterone (CA), Gen-Medroxy (CA), Novo-Medrone (CA), PMS-Medroxyprogesterone (CA), Provera, Ratio-MPA

Pharmacologic class: Hormone

Therapeutic class: Progestin

Pregnancy risk category X

FDA Box Warning

• Injection form may cause significant bone density loss. Loss increases with duration of use and may not be completely reversible. It is unknown if use during adolescence or early adulthood reduces peak bone mass and increases risk for osteoporotic fracture later in life.

• Injection form should be used as long-term contraceptive (more than 2 years) only if other contraceptive methods are inadequate.

Action

Inhibits pituitary gonadotropin secretion, preventing follicular maturation, ovulation, and pregnancy

Availability

Suspension for depot injection: 150 mg/ml, 400 mg/ml

Suspension for depot subcutaneous injection: 104 mg/0.65 ml in prefilled single-use syringes

Tablets: 2.5 mg, 5 mg, 10 mg

Indications and dosages

Secondary amenorrhea

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting at any time during menstrual cycle

Dysfunctional uterine bleeding; menses induction

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting on day 16 or 21 of menstrual cycle

To prevent estrogen-related endometrial changes in postmenopausal women

Adults: 2.5 to 5 mg/day P.O. given with 0.625 mg conjugated estrogens P.O. (monophasic regimen); or 5 mg/day P.O. on days 15 to 28 of cycle, given with 0.625 mg conjugated estrogens P.O. daily throughout cycle (biphasic regimen)

Management of endometriosis-associated pain

Adults: 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks

To prevent pregnancy

Adults: 150 mg (Depo-Provera) deep I.M. injection q 13 weeks or 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks. Give first injection during first 5 days of normal menstrual period or first 5 postpartal days if patient isn't breastfeeding, or during sixth postpartal week if patient is breastfeeding exclusively.

Renal or endometrial cancer

Adults: 400 to 1,000 mg I.M.; may repeat weekly. If improvement occurs, decrease to 400 mg q month.

Off-label uses

• Advanced breast cancer

Contraindications

• Hypersensitivity to drug or its components
• Cerebrovascular or thromboembolic disease
• Hepatic dysfunction or disease
• Breast or genital cancer
• Undiagnosed vaginal bleeding
• Known or suspected pregnancy

Precautions

Use cautiously in:
• seizure disorder, renal or cardiovascular disease, asthma, diabetes mellitus, depression, migraine
• history of hepatic disease.

Administration

• Before starting therapy, obtain thorough history and physical examination, with emphasis on breast and pelvic organs. Also obtain Pap smear, and repeat annually during therapy.
• With contraceptive use, rule out pregnancy before first dose and when more than 14 weeks have passed since previous dose.
• For I.M. injection, inject deep into gluteal, deltoid, or anterior thigh muscle. Rotate injection sites.
• Be aware that when drug is used to prevent estrogen-related endometrial changes in postmenopausal women, lowest dosage should be used for shortest time, because treatment exceeding 1 year correlates with cancer. (Some combination products have 0.3 mg estrogen/1.5 mg progesterone or 0.45 mg estrogen/1.5 mg progesterone.)

Adverse reactions

CNS: insomnia, migraine, nervousness, drowsiness, dizziness, fatigue, depression, mood changes

CV: thrombophlebitis, thromboembolism

EENT: diplopia, proptosis, retinal vascular lesions, papilledema

GI: abdominal pain, bloating

GU: amenorrhea, leukorrhea, spotting, cervical secretions, galactorrhea, breast tenderness and secretion, cervical erosions, pelvic pain, infertility

Hepatic: jaundice

Metabolic: fluid retention, hyperglycemia

Musculoskeletal: leg cramps, back pain

Respiratory: pulmonary embolism

Skin: pruritus, urticaria, rash, acne, alopecia, hirsutism, chloasma, melasma, sterile abscesses, induration at I.M. site

Other: weight and appetite changes, edema, angioedema, allergic reactions including anaphylaxis

Interactions

Drug-drug.Bromocriptine: decreased bromocriptine efficacy

Carbamazepine, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy

Drug-diagnostic tests.Alkaline phosphatase, low-density lipoproteins: increased levels

High-density lipoproteins, pregnanediol excretion: decreased levels

Thyroid hormone assays: altered results

Drug-behaviors.Alcohol use: additive CNS depression

Patient monitoring

• Monitor patient for fluid retention and for signs and symptoms of thrombophlebitis, including pain, swelling, and redness of lower legs.

Assess for visual disturbances and headache. If ocular exam shows papilledema or retinal vascular lesions, drug should be discontinued.
• Evaluate liver function tests.

Watch for abdominal pain, fever, malaise, jaundice, darkened urine, and clay-colored stools.

Patient teaching

• Advise patient that drug may cause nausea, vomiting, headache, abdominal pain, painful breast swelling, and abnormal bleeding pattern. Instruct her to report these effects if pronounced.

Tell patient to promptly report bloating, swelling, appetite loss, rash, yellowed skin, mood changes or depression, nervousness, dizziness, chest pain, shortness of breath, visual disturbances, or severe headache.
• Teach patient how to perform breast self-exams.
• Tell patient she must undergo yearly physical examinations with Pap smear.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Provera

(prō-vĕr′ə)
A trademark for a preparation of medroxyprogesterone acetate.

Provera

a trademark for a progestin (medroxyPROGESTERone acetate).

Provera

A brand name for the PROGESTOGEN drug METHYLPROGESTERONE.
References in periodicals archive ?
Mr Tronchetti Provera said the 128-year-old company expected MIRS production to boost its high performance tyre sales to 23 million in 2003, which will account for 15 per cent of total production, from 13.
PROVERA is part of the Louis Delhaize Group, also present in Europe with other banners in France like Truffaut, Animalis and Houra.
37% stake in Camfin in a move that would allow Provera to keep control of the holding company.
Marco Tronchetti Provera, chairman and CEO of the Pirelli Group stated, "Through this transaction Pirelli will strengthen its long-standing relationship with Corning and will reinvest the proceeds to further enforce its strategic role in its core businesses: telecommunications, energy transmission and tires, capturing opportunities to create additional value.
Because Natural Hormones act gently, women do not experience side-effects associated with synthetic replacement therapies like Premarin, Provera, Estrace Prempro, etc.
announced today the appointment to its International Council of Marco Tronchetti Provera, chairman and chief executive officer of Pirelli S.
After the WHI revealed differences between the estrogen-alone and estrogen-progestin study arms, implicating medroxyprogesterone acetate for increased risk of breast cancer, why is Provera still being advocated by the American College of Obstetricians and Gynecologists as a progestin safe for use in menopause?
2% stake in Pirelli Tyre SpA from its biggest shareholder, Camfin SpA, which is controlled by the family of Pirelli chairman Marco Tronchetti Provera.
Buyer: Intesa Sanpaolo SpA, UniCredit SpA , Marco Tronchetti Provera, Rosneft OAO, Nuove Partecipazioni SRL
Pirelli is in the third year of its agreement to supply tires to F1, and Tronchetti Provera does not rule out the possibility of extending the company's deal beyond 2015, the report added.
Provera also visited the Knesset, Israel's parliament in Jerusalem, as a guest of Samaria's Regional Council.
INTER MILAN are no longer interested in signing Manchester City forward CARLOS TEVEZ, according to Nerazzurri board member Marco Tronchetti Provera.